SCHEMBL433711

SCHEMBL433711

C[N+](C)(C)[PH](On1nnc2ccccc21)([N+](C)(C)C)[N+](C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
SLC9A1 P19634 3/20 0.47
KEAP1 Q14145 1/20 0.47
KMT2A Q03164 5/20 0.44
HDAC3 O15379 3/20 0.43
HDAC4 P56524 3/20 0.43
HDAC1 Q13547 3/20 0.43
HDAC7 Q8WUI4 3/20 0.43
HDAC2 Q92769 3/20 0.43
HDAC10 Q969S8 3/20 0.43
HDAC11 Q96DB2 3/20 0.43
HDAC8 Q9BY41 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
HDAC9 Q9UKV0 3/20 0.43
HDAC5 Q9UQL6 3/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL58561 0.81 TSHR (0.49) TSHRNPSR1RXFP1SLC9A1KEAP1
Fluoride SCHEMBL6346 0.80 TSHR (0.47) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL16497703 0.79 TSHR (0.53) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL16004772 0.78 TSHR (0.49) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL15967708 0.78 TSHR (0.49) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL23146638 0.77 TSHR (0.54) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL936121 0.76 TSHR (0.44) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL798347 0.76 TSHR (0.58) TSHRNPSR1RXFP1SLC9A1KEAP1
Fluoride SCHEMBL29274482 0.75 TSHR (0.43) TSHRNPSR1RXFP1SLC9A1KEAP1
SCHEMBL29389351 0.75 TSHR (0.61) TSHRNPSR1RXFP1SLC9A1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635573-A1 HETEROCYCLIC COMPOUNDS AS S1P1 AGONISTS FOR THE TREATMENT OF AUTOIMMUNE AND VASCULAR DISEASES Bristol-Myers Squibb Company (US) 2013-09-11 EP disclosed
EP-2595969-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS Bristol-Myers Squibb Company (US) 2013-05-29 EP disclosed
US-8399451-B2 Heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-19 US disclosed
EP-2560969-A1 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2013-02-27 EP disclosed
WO-2012061459-A1 HETEROCYCLIC COMPOUNDS AS S1P1 AGONISTS FOR THE TREATMENT OF AUTOIMMUNE AND VASCULAR DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2012-05-10 WO disclosed
WO-2012012477-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-26 WO disclosed
WO-2011133734-A1 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-27 WO disclosed